Capricor Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

-Conference Dates: September 13–15, 2021-

LOS ANGELES, Sept. 07, 2021 (GLOBE NEWSWIRE) —

Capricor Therapeutics

(NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that Linda Marbán, Ph.D., Capricor’s CEO, will present at the H.C. Wainwright 23

rd

Annual Global Investment Conference being held virtually from September 13



15, 2021.

The company’s on-demand presentation will be available at 7:00 a.m. Eastern time on September 13, 2021 and accessed from the H.C. Wainwright’s events platform

here

. An archived replay of the presentation will be available following the conference on the company’s website.

Management will conduct one-on-one meetings with institutional investors during the conference. If you are interested in arranging a one-on-one meeting, please contact your H.C. Wainwright representative. For more information about the

23


rd


Annual Global Investment Conference

, please visit the H.C. Wainwright conference website

Annual Global Investor Conference



.


About Capricor Therapeutics


Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company focused on developing transformative cell and exosome-based therapeutics and vaccines for treating and preventing a broad spectrum of diseases. Capricor’s lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in clinical development for treating Duchenne muscular dystrophy and the cytokine storm associated with COVID-19. Capricor is also developing its exosome technology as a next-generation therapeutic platform. The Company’s current focus is on developing exosomes loaded with nucleic acids, including mRNA, to treat or prevent a variety of diseases. For more information, visit

www.capricor.com

, and follow the Company on

Facebook

,

Instagram

and

Twitter

.


Cautionary Note Regarding Forward-Looking Statements


Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; plans regarding current and future collaborative activities and the ownership of commercial rights; scope, duration, validity and enforceability of intellectual property rights; future royalty streams, revenue projections; expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings; and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2020 as filed with the Securities and Exchange Commission on March 15, 2021 and in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 as filed with the Securities and Exchange Commission on August 13, 2021. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.


CAP-1002 is an Investigational New Drug and is not approved for any indications. None of Capricor’s exosome-based candidates have been approved for clinical investigation.

For more information, please contact:


Media Contact

:

Caitlin Kasunich / Raquel Cona

KCSA Strategic Communications

[email protected] / [email protected]

212.896.1241 / 212.896.1204


Investor Contact

:

Joyce Allaire

LifeSci Advisors, LLC

[email protected]

617.435.6602


Company Contact

:

AJ Bergmann, Chief Financial Officer

[email protected]

310.358.3200



Primary Logo